Aimovig

Active Ingredient(s): Erenumab-aooe
FDA Approved: * May 17, 2018
Pharm Company: * AMGEN INC
Category: Migraine / Tension Headache

Erenumab, sold under the brand name Aimovig, is a medication which targets the calcitonin gene-related peptide receptor (CGRPR) for the prevention of migraine.[2][3][4] Erenumab was approved in May 2018 and was the first of a group of four CGRPR antagonists to be approved by the U.S. Food and Drug Administration (FDA) that year. It is a form of monoclonal antibody therapy in which antibodies are used to block the receptors for the protein CGRP, ... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Aimovig 70 mg/ml Subcutaneous Injection
NDC: 55513-840
Labeler:
Amgen Inc
Aimovig 70 mg/ml Subcutaneous Injection
NDC: 55513-841
Labeler:
Amgen Inc
Aimovig 140 mg/ml Subcutaneous Injection, Solution
NDC: 55513-842
Labeler:
Amgen Inc
Aimovig 140 mg/ml Subcutaneous Injection, Solution
NDC: 55513-843
Labeler:
Amgen Inc